Salarius Pharmaceuticals has entered into a securities purchase agreement allowing it to sell up to $10 million in shares to C/M Capital Master Fund, with specific conditions and pricing terms outlined. The proceeds will be used for working capital and corporate purposes, and the agreement includes a registration rights agreement for resale of the shares.